2022-06-03 | NDAQ:NEO | Press release

Gibbs Law Group investigates potential violations of securities law

Shares of NeoGenomics Inc. fell more than 20% on March 28, 2022, after the company announced disappointing guidance in its quarterly report, in addition to the departure of CEO Mark Mallon. On May 31, 2022, InvestorsObserver gave NeoGenomics a neutral score. Gibbs Law Group is investigating a potential Class action against NeoGenomics Securities on behalf of shareholders who lost money in NeoGenomics Inc. (NASDAQ: NEO).

To speak to a lawyer regarding this class action investigation, Click here Where call (888) 410-2925.

On Monday, March 28, 2022, shares of health testing company NeoGenomics fell after it announced in its quarterly report that CEO Mark Mallon would leave after just a year as in the role, and that the company will run out of guidance and cancel its forecast for the whole year. According Market watch,NeoGenomics’ the stock has been losing ground since a November 2021 report announced disappointing forecasts. Over the past year, NeoGenomics has lost around 76%. of its value, according to Yahoo Finance, going from a market cap of $6 billion at times to around $1.01 billion at market close on Friday, June 3, 2022.

According Investor’s Business Daily, Needham analyst Mike Matson raised the possibility that Mallon invested too much in the NeoGenomics minimal residual disease test, which looks for cancer in a patient’s blood after treatment. These investments would have influenced NeoGenomics’ earnings before interest, taxes, depreciation and amortization, or EBITDA.

Following this news, NeoGenomics’ stock price fell more than 20% on March 28e2022, causing significant harm to investors.

May 12e, 2022, NeoGenomics announced the appointment of Lynn Tetrault, Esq. as Chairman of the Board and Interim Chief Executive Officer. Ms Tetrault has served as executive chairman since the company’s former CEO, Mark Mallon, agreed to step down in March 2022.

What should NeoGenomics investors do?

If you have invested in NeoGenomics, visit our website or contact our securities team directly at (888) 410-2925 to discuss how you might recoup your losses. Our investigation focuses on whether NeoGenomics violated federal securities laws by providing false or misleading statements to investors.

About Gibbs Law Group

Gibbs Law Group represents investors nationwide in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duties and breaches of powers of attorney. The firm has recovered over $1 billion for its clients against some of the world’s largest corporations, and our attorneys have received numerous accolades for their work, including “Best Lawyers in America,” “Best Plaintiffs’ Attorneys in California,” “California Lawyer of the Year,” “Class Action Practice Group of the Year, ” “Consumer Protection MVP,” and “Top Women Lawyers in California.”

This press release may constitute attorney publicity in certain jurisdictions under applicable law and ethics rules.

Comments are closed.